# A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery

> **NCT05550350** · PHASE3 · WITHDRAWN · sponsor: **EyePoint Pharmaceuticals, Inc.**

## Conditions studied

- Cataract

## Interventions

- **DRUG:** Dexycu
- **OTHER:** Placebo/Vehicle

## Key facts

- **NCT ID:** NCT05550350
- **Lead sponsor:** EyePoint Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No longer pursuing indication
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05550350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05550350, "A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05550350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*